{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T04:29:32Z","timestamp":1769315372290,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Dermatol Res"],"DOI":"10.1007\/s00403-025-03959-9","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T10:54:04Z","timestamp":1739616844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A pharmacovigilance analysis of abrocitinib-related skin adverse events based on the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1007","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2788-1287","authenticated-orcid":false,"given":"Min","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1768-7172","authenticated-orcid":false,"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"issue":"1","key":"3959_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40257-023-00827-y","volume":"25","author":"C Vestergaard","year":"2024","unstructured":"Vestergaard C, Skovsgaard C, Johansen C et al (2024) Treat-to-target in atopic dermatitis [J]. Am J Clin Dermatol 25(1):91\u201398","journal-title":"Am J Clin Dermatol"},{"key":"3959_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.micres.2023.127595","volume":"281","author":"S Mohammad","year":"2024","unstructured":"Mohammad S, Karim MR, Iqbal S et al (2024) Atopic dermatitis: pathophysiology, microbiota, and metabolome\u2014a comprehensive review [J]. Microbiol Res 281:127595","journal-title":"Microbiol Res"},{"issue":"1","key":"3959_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaip.2019.06.044","volume":"8","author":"AB Fishbein","year":"2020","unstructured":"Fishbein AB, Silverberg JI, Wilson EJ et al (2020) Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection [J]. J Allergy Clin Immunol Pract 8(1):91\u2013101","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"3959_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","volume":"139","author":"ZC Chiesa Fuxench","year":"2019","unstructured":"Chiesa Fuxench ZC, Block JK, Boguniewicz M et al (2019) Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population [J]. J Invest Dermatol 139(3):583\u2013590","journal-title":"J Invest Dermatol"},{"key":"3959_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1367099","author":"Z Yu","year":"2024","unstructured":"Yu Z, Rui-Lian D, Jin B (2024) Effectiveness and safety of systemic therapy for moderate-to-severe atopic dermatitis in children and adolescent patients: a systematic review [J]. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1367099","journal-title":"Front Immunol"},{"issue":"2","key":"3959_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40257-018-0413-2","volume":"20","author":"H He","year":"2019","unstructured":"He H, Guttman-Yassky E (2019) JAK inhibitors for atopic dermatitis: an update [J]. Am J Clin Dermatol 20(2):181\u2013192","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"3959_CR7","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1002\/art.41906","volume":"73","author":"C Liu","year":"2021","unstructured":"Liu C, Kieltyka J, Fleischmann R et al (2021) A decade of JAK inhibitors: what have we learned and what may be the future? [J]. Arthritis Rheumatol 73(12):2166\u20132178","journal-title":"Arthritis Rheumatol"},{"issue":"18","key":"3959_CR8","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1007\/s40265-021-01638-3","volume":"81","author":"ED Deeks","year":"2021","unstructured":"Deeks ED, Duggan S (2021) Abrocitinib: first approval [J]. Drugs 81(18):2149\u20132157","journal-title":"Drugs"},{"issue":"3","key":"3959_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","volume":"13","author":"C Samuel","year":"2023","unstructured":"Samuel C, Cornman H, Kambala A et al (2023) A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring [J]. Dermatol Ther (Heidelb) 13(3):729\u2013749","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"3959_CR10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jaad.2022.04.009","volume":"87","author":"VY Shi","year":"2022","unstructured":"Shi VY, Bhutani T, Fonacier L et al (2022) Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND) [J]. J Am Acad Dermatol 87(2):351\u2013358","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"3959_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s00403-024-03109-7","volume":"316","author":"P Jean-Pierre","year":"2024","unstructured":"Jean-Pierre P, Nouri K (2024) A retrospective analysis of drugs associated with the development of cutaneous squamous cell carcinoma reported by patients on the FDA\u2019s adverse events reporting system [J]. Arch Dermatol Res 316(6):250","journal-title":"Arch Dermatol Res"},{"issue":"8","key":"3959_CR12","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1002\/pds.5624","volume":"32","author":"P Trillenberg","year":"2023","unstructured":"Trillenberg P, Sprenger A, Machner B (2023) Sensitivity and specificity in signal detection with the reporting odds ratio and the information component [J]. Pharmacoepidemiol Drug Saf 32(8):910\u2013917","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"3959_CR13","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s40264-024-01433-5","volume":"47","author":"CA Gravel","year":"2024","unstructured":"Gravel CA, Bai W, Douros A (2024) Comparators in pharmacovigilance: a quasi-quantification bias analysis [J]. Drug Saf 47(8):809\u2013819","journal-title":"Drug Saf"},{"issue":"7","key":"3959_CR14","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1517\/14740338.2014.915938","volume":"13","author":"Y Hou","year":"2014","unstructured":"Hou Y, Ye X, Wu G et al (2014) A comparison of disproportionality analysis methods in national adverse drug reaction databases of China [J]. Expert Opin Drug Saf 13(7):853\u2013857","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"3959_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/bjd\/ljad339","volume":"190","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yang Y et al (2023) Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study [J]. Br J Dermatol 190(1):55\u201361","journal-title":"Br J Dermatol"},{"issue":"12","key":"3959_CR16","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3510","volume":"100","author":"S Bylund","year":"2020","unstructured":"Bylund S, Kobyletzki LB, Svalstedt M et al (2020) Prevalence and incidence of atopic dermatitis: a systematic review [J]. Acta Derm Venereol 100(12):adv00160","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"3959_CR17","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/pde.13991","volume":"37","author":"K Capozza","year":"2020","unstructured":"Capozza K, Schwartz A (2020) Does it work and is it safe? Parents\u2019 perspectives on adherence to medication for atopic dermatitis [J]. Pediatr Dermatol 37(1):58\u201361","journal-title":"Pediatr Dermatol"},{"issue":"10246","key":"3959_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S et al (2020) Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial [J]. Lancet 396(10246):255\u2013266","journal-title":"Lancet"},{"issue":"12","key":"3959_CR19","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s40264-015-0341-5","volume":"38","author":"AC Pacurariu","year":"2015","unstructured":"Pacurariu AC, Straus SM, Trifir\u00f2 G et al (2015) Useful interplay between spontaneous ADR reports and electronic healthcare records in signal detection [J]. Drug Saf 38(12):1201\u20131210","journal-title":"Drug Saf"},{"issue":"6","key":"3959_CR20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1007\/s40264-015-0289-5","volume":"38","author":"G Candore","year":"2015","unstructured":"Candore G, Juhlin K, Manlik K et al (2015) Comparison of statistical signal detection methods within and across spontaneous reporting databases [J]. Drug Saf 38(6):577\u2013587","journal-title":"Drug Saf"},{"issue":"6","key":"3959_CR21","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/pds.964","volume":"13","author":"K Kubota","year":"2004","unstructured":"Kubota K, Koide D, Hirai T (2004) Comparison of data mining methodologies using Japanese spontaneous reports [J]. Pharmacoepidemiol Drug Saf 13(6):387\u2013394","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"3959_CR22","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","volume":"72","author":"JL Montastruc","year":"2011","unstructured":"Montastruc JL, Sommet A, Bagheri H et al (2011) Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database [J]. Br J Clin Pharmacol 72(6):905\u2013908","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"3959_CR23","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/02770903.2024.2311236","volume":"61","author":"MG Matera","year":"2024","unstructured":"Matera MG, Ora J, Calzetta L et al (2024) Biologics for asthma and risk of pneumonia [J]. J Asthma 61(9):905\u2013911","journal-title":"J Asthma"},{"key":"3959_CR24","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.2147\/CCID.S440138","volume":"16","author":"M Ren","year":"2023","unstructured":"Ren M, Yang X, Teng Y et al (2023) Successful treatment of granulomatous rosacea by JAK inhibitor abrocitinib: a case report [J]. Clin Cosmet Investig Dermatol 16:3369\u20133374","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"3959_CR25","doi-asserted-by":"publisher","first-page":"2242706","DOI":"10.1080\/09546634.2023.2242706","volume":"34","author":"J Zhang","year":"2023","unstructured":"Zhang J, Zuo YG (2023) Successful treatment of alopecia universalis with abrocitinib: a case report [J]. J Dermatolog Treat 34(1):2242706","journal-title":"J Dermatolog Treat"},{"key":"3959_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2147\/CCID.S446369","volume":"17","author":"P Chen","year":"2024","unstructured":"Chen P, Liang J, Li C et al (2024) Abrocitinib as a novel treatment for multiple skin disorders: 3 case reports and a scoping review [J]. Clin Cosmet Investig Dermatol 17:35\u201340","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"2","key":"3959_CR27","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1080\/09546634.2019.1589643","volume":"31","author":"Y Yao","year":"2020","unstructured":"Yao Y, Ravn J\u00f8rgensen AH, Thomsen SF (2020) Biologics for chronic inflammatory skin diseases: an update for the clinician [J]. J Dermatolog Treat 31(2):108\u2013130","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"3959_CR28","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1097\/CM9.0000000000002838","volume":"137","author":"Y Hu","year":"2024","unstructured":"Hu Y, Zhao Y, Li H et al (2024) Good efficacy and safety profile of abrocitinib in Chinese adult patients with atopic dermatitis: a case series study [J]. Chin Med J (Engl) 137(6):740\u2013742","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"3959_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1517\/14740338.3.5.471","volume":"3","author":"EK Tan","year":"2004","unstructured":"Tan EK, Grattan CE (2004) Drug-induced urticaria [J]. Expert Opin Drug Saf 3(5):471\u2013484","journal-title":"Expert Opin Drug Saf"},{"key":"3959_CR30","doi-asserted-by":"publisher","first-page":"1279139","DOI":"10.3389\/fimmu.2023.1279139","volume":"14","author":"W Su","year":"2023","unstructured":"Su W, Tian Y, Wei Y et al (2023) Key genes and immune infiltration in chronic spontaneous urticaria: a study of bioinformatics and systems biology [J]. Front Immunol 14:1279139","journal-title":"Front Immunol"},{"issue":"1","key":"3959_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1385\/CRIAI:30:1:019","volume":"30","author":"P Mathelier-Fusade","year":"2006","unstructured":"Mathelier-Fusade P (2006) Drug-induced urticarias [J]. Clin Rev Allergy Immunol 30(1):19\u201323","journal-title":"Clin Rev Allergy Immunol"},{"issue":"8","key":"3959_CR32","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1111\/bcp.15490","volume":"90","author":"BR Del Pozzo-Maga\u00f1a","year":"2024","unstructured":"Del Pozzo-Maga\u00f1a BR, Liy-Wong C (2024) Drugs and the skin: a concise review of cutaneous adverse drug reactions [J]. Br J Clin Pharmacol 90(8):1838\u20131855","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"3959_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12933","volume":"32","author":"BJ Doolan","year":"2019","unstructured":"Doolan BJ, Cranwell WC, Varigos GA et al (2019) An urticarial drug eruption caused by tofacitinib for alopecia universalis [J]. Dermatol Ther 32(4):e12933","journal-title":"Dermatol Ther"},{"issue":"3","key":"3959_CR34","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2165\/00128071-200102030-00004","volume":"2","author":"D Shipley","year":"2001","unstructured":"Shipley D, Ormerod AD (2001) Drug-induced urticaria. Recognition and treatment [J]. Am J Clin Dermatol 2(3):151\u2013158","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"3959_CR35","first-page":"1127","volume":"14","author":"GG Mitroi","year":"2024","unstructured":"Mitroi GG, Mitroi GF, Ic\u0103 OM et al (2024) Off-label uses of abrocitinib: review of emerging therapeutic applications beyond atopic dermatitis [J]. Life (Basel) 14(9):1127","journal-title":"Life (Basel)"},{"key":"3959_CR36","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v104.39822","volume":"104","author":"Y Li","year":"2024","unstructured":"Li Y, Tan X, Nie S et al (2024) Real-world experience of abrocitinib on difficult-to-treat hand eczema in Chinese patients [J]. Acta Derm Venereol 104:adv39822","journal-title":"Acta Derm Venereol"},{"key":"3959_CR37","doi-asserted-by":"publisher","first-page":"1416004","DOI":"10.3389\/fimmu.2024.1416004","volume":"15","author":"T Zhang","year":"2024","unstructured":"Zhang T, Liu X, Zhang L et al (2024) Treatment of rosacea with upadacitinib and abrocitinib: case report and review of evidence for Janus kinase inhibition in rosacea [J]. Front Immunol 15:1416004","journal-title":"Front Immunol"},{"issue":"6","key":"3959_CR38","first-page":"88","volume":"119","author":"I Kremenevski","year":"2022","unstructured":"Kremenevski I, Sander O, Sticherling M et al (2022) Paradoxical reactions to biologicals in chronic inflammatory systemic diseases [J]. Dtsch Arztebl Int 119(6):88\u201395","journal-title":"Dtsch Arztebl Int"},{"issue":"2","key":"3959_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2015-000239","volume":"2","author":"\u00c9 Toussirot","year":"2016","unstructured":"Toussirot \u00c9, Aubin F (2016) Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview [J]. RMD Open 2(2):e000239","journal-title":"RMD Open"},{"key":"3959_CR40","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fphar.2019.00282","volume":"10","author":"S Garcovich","year":"2019","unstructured":"Garcovich S, de Simone C, Genovese G et al (2019) Paradoxical skin reactions to biologics in patients with rheumatologic disorders [J]. Front Pharmacol 10:282","journal-title":"Front Pharmacol"}],"container-title":["Archives of Dermatological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03959-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00403-025-03959-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00403-025-03959-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T10:54:08Z","timestamp":1739616848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00403-025-03959-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3959"],"URL":"https:\/\/doi.org\/10.1007\/s00403-025-03959-9","relation":{},"ISSN":["1432-069X"],"issn-type":[{"value":"1432-069X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"4 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"419"}}